IMR Press / FBL / Volume 11 / Issue 1 / DOI: 10.2741/1813

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Primary gastrointestinal stromal tumor of the liver with lung metastases successfully treated with STI-571 (imatinib mesylate)
Show Less
1 U.O.C. Pathology, Istituto dei Tumori di Napoli “G. Pascale”, Italy
2 U.O.C. Radiology, Istituto dei Tumori di Napoli “G. Pascale”, Italy
3 U.O.C. Nuclear Medicine, Istituto dei Tumori di Napoli “G. Pascale”, Italy
4 U.O.C. Medical Oncology B, Istituto dei Tumori di Napoli “G. Pascale”, Italy
Academic Editor:Antonio Giordano
Front. Biosci. (Landmark Ed) 2006, 11(1), 498–501; https://doi.org/10.2741/1813
Published: 1 January 2006
(This article belongs to the Special Issue Gene targets for modulating cell growth)
Abstract

We report a case of a primary malignant GIST of the liver metastatic to the lung in a 37 years-old man. The liver tumor showed histological feature of a GIST and expressed vimentin, and diffusely exhibited CD117. One year after the resection of the liver mass, the patient developed multiple small lung metastases which completely disappeared with STI-571 (imatinib mesylate – Gleevec) therapy. C.T. or PET did not show any mass in the abdomen. These findings suggest that the liver mass was a primary rather than a metastatic tumour. They also support the hypothesis that GIST could originate from undifferentiated mesenchymal cells capable to differentiate toward a pacemaker cell phenotype, which are present in sites other than the G.I. tract.

Share
Back to top